Funding Opportunities

The NCI Division of Cancer Prevention funds new research in cancer prevention, detection, screening, interception, and symptom management. We also fund programs to train people for careers in research. Explore current open funding opportunities here and streamline your search by using keyword or type of funding.

Information about the funding opportunity announcements that align with the efforts of the Cancer MoonshotSM can be found here: https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/funding.

Request for Proposals (Contracts)

Title Fast-Track Proposals Direct-to-Phase II Proposals Receipt date Anticipated Awards Budget

NIH/NCI 459 – Automated Software for Point-of-Care Testing to Identify Cancer-Associated Malnutrition

 Accepted NOT Accepted 11/14/2023 2-3 Phase I: up to $400,000 for up to 12 months
Phase II: up to $2,000,000 for up to 2 years

NIH/NCI 456– Rapid and Affordable Point-of-Care HPV Diagnostics for Cervical Cancer Control

 Accepted Accepted 11/14/2023 3-5 Phase I: up to $400,000 for up to 12 months
Phase II: up to $2,000,000 for up to 2 years

Notice of Funding Opportunities

Title Announcement Number Activity Code Clinical Trials Status Expiration Date Program Official
Biology of Bladder Cancer PAR-22-219 (R21 Clinical Trial Optional) R21 Clinical Trial Optional 09/08/2025 Chen Suen, Ph.D., R.Ph.
Stephen I. Katz Early Stage Investigator Research Project Grant PAR-21-039 (R01 Basic Experimental Studies with Humans Required) R01 12/29/2023
Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment-Related Cardiotoxicity NOT-CA-22-001 11/06/2024
Notice of Special Interest (NOSI): Leveraging Real-World Imaging Data for Artificial Intelligence-based Modeling and Early Detection of Abdominal Cancers NOT-CA-21-028 01/08/2024 Natalie Abrams, Ph.D.
HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices RFA-NS-23-003 (RM1 Clinical Trial Optional) RM1 Clinical Trial Optional 06/10/2025
Mechanisms that Impact Cancer Risk after Bariatric Surgery PAR-21-331 (R01 Clinical Trial Optional) R01 Clinical Trial Optional 09/08/2024 Edward Sauter, M.D., Ph.D.
Basic Research in Cancer Health Disparities PAR-21-323 (R21 Clinical Trial Not Allowed) R21 Clinical Trial Not Allowed 09/08/2024 Asad Umar, D.V.M., Ph.D.
Basic Research in Cancer Health Disparities PAR-21-324 (R03 Clinical Trial Not Allowed) R03 Clinical Trial Not Allowed 09/08/2024 Asad Umar, D.V.M., Ph.D.
Basic Research in Cancer Health Disparities PAR-21-322 (R01 Clinical Trial Not Allowed) R01 Clinical Trial Not Allowed 09/08/2024 Asad Umar, D.V.M., Ph.D.
Assay Validation of High Quality Markers for Clinical Studies in Cancer PAR-20-313 (UH2/UH3 Clinical Trial Not Allowed) UH2, UH3 Clinical Trial Not Allowed 10/11/2023 Lynn Sorbara, Ph.D.